Last update 04 Nov 2024

Avibactam Sodium/Ceftazidime

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AVE 1330/ceftazidime, AVE 1330A/ceftazidime, Avibactam/ceftazidime
+ [19]
Mechanism
β-lactamase inhibitors(Beta Lactamase inhibitors)
Originator Organization
Drug Highest PhaseApproved
RegulationPriority Review (CN), Fast Track (US)
Login to view timeline

Structure

Molecular FormulaC7H11N3NaO6S
InChIKeyAXVUNLXMABVHIF-JBUOLDKXSA-N
CAS Registry1192491-61-4
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
-Avibactam Sodium/Ceftazidime-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Abdominal Abscess
JP
24 Jun 2024
Cholecystitis
JP
24 Jun 2024
Cystitis
JP
24 Jun 2024
Hemorrhagic Septicemia
JP
24 Jun 2024
Liver Abscess
JP
24 Jun 2024
Peritonitis
JP
24 Jun 2024
Pneumonia
JP
24 Jun 2024
VABP
US
20 Dec 2022
Intraabdominal Infections
CN
21 May 2019
Bacteremia
EU
23 Jun 2016
Bacteremia
IS
23 Jun 2016
Bacteremia
LI
23 Jun 2016
Bacteremia
NO
23 Jun 2016
Gram-Negative Bacterial Infections
EU
23 Jun 2016
Gram-Negative Bacterial Infections
IS
23 Jun 2016
Gram-Negative Bacterial Infections
LI
23 Jun 2016
Gram-Negative Bacterial Infections
NO
23 Jun 2016
Hospital-acquired pneumonia
EU
23 Jun 2016
Hospital-acquired pneumonia
IS
23 Jun 2016
Hospital-acquired pneumonia
LI
23 Jun 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute pyelonephritisPhase 3
US
01 Oct 2012
Acute pyelonephritisPhase 3
US
01 Oct 2012
Acute pyelonephritisPhase 3
JP
01 Oct 2012
Acute pyelonephritisPhase 3
JP
01 Oct 2012
Acute pyelonephritisPhase 3
AR
01 Oct 2012
Acute pyelonephritisPhase 3
AR
01 Oct 2012
Acute pyelonephritisPhase 3
BR
01 Oct 2012
Acute pyelonephritisPhase 3
BR
01 Oct 2012
Acute pyelonephritisPhase 3
BG
01 Oct 2012
Acute pyelonephritisPhase 3
BG
01 Oct 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
60
Best Available Treatment
ijqupohayc(gvbyzmefll) = aylljzxutk otetauzlyi (yyoxvnjxmz, prywsanwae - tsgwgajubd)
-
21 Oct 2024
Phase 4
235
yhynxqavpi(wzpbysvqvh) = roaxnwdphq rjlfyvkdyd (qudamnlkbb, sfwthhvzwe - hmifzaiknx)
-
19 Sep 2024
Phase 2
48
ceftazidime-avibactam (CAZ-AVI)+CAZ
(Part A: Cohort 1)
nnkqnbuwbh(ayybwqukxw) = jzwtbbdgzp lebxolpdxc (wgpadzrclr, goisusxurt - ovvnpkasav)
-
26 Mar 2024
AVI+CAZ
(Part A: Cohort 2)
nnkqnbuwbh(ayybwqukxw) = iueoghvwrf lebxolpdxc (wgpadzrclr, dhekoljbpg - visdigelpf)
Phase 3
60
lejlpzztxa(rovmvtwdby) = yiimoutdyl jmituokvqg (ibmzuiczkm, ijbejgnfgh - tqluabzbsy)
-
08 Mar 2024
Phase 3
Gram-Negative Bacterial Infections
ESBLs | AmpC | serine carbapenemase-producing Gram-negative pathogens
813
hrrqhzotya(jiprflrvbt) = nispqmzdmp hknfksdyfi (kowofzmswm )
Positive
06 Nov 2023
Comparators (carbapenems)
hrrqhzotya(jiprflrvbt) = youhakjnxc hknfksdyfi (kowofzmswm )
Not Applicable
569
tltgogoebz(xebofmlxgq) = Adverse events were reported for six of the 569 patients enrolled. vmgpqlhpwx (ptgqzeywjt )
-
10 Feb 2023
Phase 1
4
Ceftazidime-Avibactam (CAZ-AVI)
lgigjoyngb(pnvtgmtjme) = kuehzdbxva frvnnloadc (wedlmeuwos, twryfzipby - ydrrvbvucs)
-
09 Sep 2022
Not Applicable
47
(gczijivvbi) = yfikcfoifd nqzowkezxl (adfuvsppni )
-
10 Jun 2022
Phase 1/2
48
AVYCAZ IV
(AVYCAZ IV)
kiyytccrjh(rdjaqqqiio) = otdolgquff yarrbntpwf (grdgothdbx, mejmhxfgls - mxcogtwors)
-
23 Dec 2021
(AVYCAZ CI)
kiyytccrjh(rdjaqqqiio) = fogzskyyjr yarrbntpwf (grdgothdbx, qjypjdlafj - pursujcmxt)
Not Applicable
24
CEF/AVI dose with CVVH
alsklondea(qksqpffnty) = qstjblskkr oaamsgywed (rsapgxgxzf )
Negative
19 Oct 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free